Ashley Ghiaseddin is a Neurology physician affiliated with University of Florida Health. OpenAlex indexes 92 publications with 774 citations (h-index 12); ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1600 SW Archer Rd
Gainesville, FL 326102859
Telephone
352-273-9000Registry record last updated 25 Apr 2018.
Clinical trials
- RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
Sponsor: University of Florida
- ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients
Sponsor: University of Florida
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novocure Inc.Program year20254 payments
- Telix PharmaceuticalsProgram year202516 payments
- SERVIER PHARMACEUTICALS LLCProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
78.9%Kinase inhibitor57.9%Cotellic33%Sunitinib Malate33%Zelboraf33%Part D<11 patientsAlkylating Drug21.1%Gleostine100%Part D<11 patientsNervous system
21.1%Other antiepileptics21.1%Levetiracetam100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Targeting immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response
Journal of Clinical Investigation
2025 - Systemic mRNA vaccines elicit rapid immune activation in canine brain tumors
Journal for ImmunoTherapy of Cancer
2025 - A Rare Presentation of Adult Primary Leptomeningeal Medulloblastoma: Case Report
Case Reports in Pathology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
John Wingard, MD
University of Florida Health
Barry Byrne, MD
University of Florida Health
Gilbert Upchurch, MD
University of Florida Health
Carmen Allegra, MD
University of Florida Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”